Bioage Labs, INC S-1 registration statements

BioAge Labs has filed a registration statement to increase its common stock offering by 575,000 shares, including an underwriter's option, representing no more than 20% of the prior offering's maximum aggregate price.

BioAge Labs is seeking to raise $180 million through an IPO to fund the development of its pipeline, including azelaprag for metabolic diseases and NLRP3 inhibitors for neuroinflammation.

BioAge Labs is seeking to raise $163.9 million through an IPO to fund the development of its therapeutics targeting metabolic diseases by leveraging insights into human aging biology.

BioAge Labs, a clinical-stage biopharmaceutical company, has filed for an initial public offering to advance its pipeline of therapeutics targeting metabolic diseases by leveraging insights into the biology of human aging.